CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Handicare Bathroom Safety B.V.

Lakemary

Founded in 1969, Lakemary is in America’s Heartland. Our main campus and ranch are on 32 acres in the quiet town of Paola, KS just south of Kansas City. Our...

the SYNERGY HEALTH

Norwich Pharmaceuticals

Norwich Pharmaceuticals, Inc. is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Euro Pharma

Euro Pharma is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.